THE CHEMOURS COMPANY

Q3 2025 EARNINGS PRESENTATION

November 7, 2025

Safe Harbor Statement and Other Matters

Chemours™

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the fourth quarter of 2025, the full year 2025 and the Company's refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the U.S. or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this presentation, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flow, Free Cash Flow Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this presentation, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this presentation may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

Third Quarter 2025 Highlights

Generated $1.5B in Net Sales and $195M in Adjusted EBITDA

Achieved 80% YoY Net Sales growth for Opteon™ Refrigerants in TSS, reflecting continued strong adoption

Announced the successful qualification of Chemours' two-phase immersion cooling fluid by Samsung Electronics

Strategic agreement with SRF Limited in India to support market needs for essential applications

Published 2024 Sustainability Report detailing significant progress against 2030 Corporate Responsibility Commitment goals

Third Quarter 2025 Financial Summary

($ in millions unless otherwise noted; excludes per share amounts)

	3Q25	3Q24 [5]	Y-o-Y Δ	2Q25	Q-o-Q Δ
Net Sales	**$1,495**	**$1,508**	**($13)**	**$1,615**	**($120)**
Net Income / (Loss) [1]	$60	($32)	$92	($381)	$441
Adj. Net Income [2]	$30	$61	($31)	$87	($57)
EPS [3]	**$0.40**	**($0.22)**	**$0.62**	**($2.54)**	**$2.94**
Adj. EPS [2,3]	**$0.20**	**$0.40**	**($0.20)**	**$0.58**	**($0.38)**
Adj. EBITDA [2,4]	**$195**	**$202**	**($7)**	**$253**	**($58)**
Operating Cash Flow	$146	$139	$7	$93	$53
Capex	$41	$76	($35)	($43)	$84
Free Cash Flow	**$105**	**$63**	**$42**	**$50**	**$55**
FCF Conversion	54%	31%	23%	20%	34%

1 Net (Loss) / Income attributable to The Chemours Company.

2 Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items. Please refer to the attached "GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.

3 Calculation based on diluted share count.

4 Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached "GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited)" table.

5 As previously disclosed in the first quarter of 2025, certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Quarterly Report on Form 10-Q for the three months ended September 30, 2025.

Adjusted EBITDA Bridge: 3Q25 versus 3Q24

($ in millions)



Price Impacts: $7 million due to higher pricing in TSS primarily driven by stronger Opteon™ Refrigerant blends aftermarket demand and strong pricing in APM, in connection with increased sales into high-value applications as well as solid sales execution for our SPS Capstone™ product line wind down, partially offset by lower pricing globally in TT
Volume Impacts: $18 million primarily driven by increased volumes in TSS's Opteon™ Refrigerant blends, partially offset by decreased volumes in APM
Cost/Other: ($47) million primarily driven by higher input and operational costs in TT, one-time outage impact in APM, and input cost increases driven by R32 refrigerant and liquid cooling product development costs in TSS, partially offset by lower Corporate Expenses
Currency: $15 million primarily driven by favorable currency in TT

[5] Refer to footnote provided on the preceding slides.

Quarterly Segment Summary

($ in millions unless otherwise noted)

Net Sales [5]



Adjusted EBITDA and Margin [5] (%)



[5] Refer to footnote provided on the preceding slides.

Liquidity Position as of September 30, 2025

($ in millions unless otherwise noted)

Total Liquidity [9]	$1.6B
Gross Debt	$4.2B
Net Debt [10]	$3.6B
TTM Net Leverage [11]	4.6x



6 Total cash balances include $52 million and $51 million of restricted cash and restricted cash equivalents on Chemours' Balance Sheets as of September 30, 2025 and June 30, 2025, respectively. Restricted cash of $51 million at the end of the second quarter and $52 million at the end of the third quarter includes cash and cash equivalents held in escrow under the terms of the Memorandum of Understanding (MOU) related to potential future legacy liabilities.

7 Cash to shareholders reflects $13 million in dividends paid to shareholders during the third quarter of 2025.

8 Other primarily includes favorable FX impact on cash net of debt repayments.

9 Total liquidity is calculated as the sum of $613 million unrestricted cash and cash equivalents and $953 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents totaling $52 million is not included in this calculation. The Company announced an amendment and extension to its credit agreement in May 2025. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion until October 2026, comprised of $780 million maturing on May 2, 2030 and $220 million on October 7, 2026.

10 Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents.

11 TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA.

Chemours™

STRATEGIC PROGRESS

PATHWAY TO THRIVE

Our Strategy

PATHWAY TO THRIVE

Operational Excellence	Enabling Growth	Portfolio Management	Strengthening the Long-Term
❑ Manufacturing excellence as a basis for success ❑ Improved and standardized operating model for consistent execution ❑ Continuous improvement to adapt to changing markets	❑ Investing smartly in selected growth projects ❑ Commercial effectiveness to drive sales growth ❑ Innovation and new product development	❑ Holistic portfolio analysis focused on distinct value creation metrics ❑ Shift product mix to higher value applications in growing end markets ❑ Optimize asset footprint	❑ Measurable progress on resolving legacy liabilities in the interest of stakeholders ❑ Responsible manufacturing practices ❑ Targeted policy efforts
>$250M cost reduction from 2024 to 2027	>5% Sales CAGR from 2024 to 2027	Driving shareholder value	Recognizing criticality of our chemistries

Balanced & Disciplined Capital Allocation To Create Shareholder Value

Progress Achieved to Date

PATHWAY TO THRIVE

Operational Excellence	Enabling Growth	Portfolio Management	Strengthening the Long-Term
✓ On track to deliver ~$125M of gross cost savings within Chemours' control by end of 2025 across all areas of the company ✓ Operational matters have been resolved across Chemours' sites, a key focus for the executive leadership team this quarter ✓ Launched the Chemours Business System to embed Lean principles across operations, driving safety, quality, and efficiency improvements company-wide	✓ Continued double-digit growth with 80% YoY quarterly growth in Opteon™ Refrigerants, with an advantaged market position to secure aftermarket share ✓ Highlighting mineral separation expertise and the current $90M of mineral sales, roughly half of which is Precision Investment Casting Zircon and Monazite, which support essential industrial and military applications ✓ Successful qualification of Chemours' two-phase immersion cooling fluid by Samsung Electronics	✓ Strategic agreement with SRF Limited in India to support market needs for essential applications ✓ Progressed APM European asset review, including the exit of SPS Capstone™ business, to prioritize higher return businesses and strengthen Chemours' overall portfolio	✓ Agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all environmental claims, including PFAS statewide ✓ Drove advocacy for the importance of Chemours' essential chemistry as a part of U.S. trade policy changes and evolving EU regulatory landscape ✓ Detailed significant progress against 2030 CRC goals in 2024 Sustainability Report ✓ EPA starts priority review for new chemicals supporting data center projects; including liquid cooling[1]

Balanced & Disciplined Capital Allocation To Create Shareholder Value

[1] EPA Prioritizes Review of New Chemicals Used in Data Center Projects, Supporting American Manufacturing and Technological Advancement

2024 Sustainability Report Highlights

Reduced total process FOC emissions 76%*—on our way to a 99% or more reduction by 2030

Achieved 52%* reduction of operational GHG emissions—on track to meet our 60% reduction by 2030

Accomplished the 2030 Sustainable Offerings goal 6 years early; 50% of revenue now coming from products that specifically contribute to the UN Sustainable Development Goals

Completed first Double Materiality Assessment, supporting further alignment of our sustainability priorities with stakeholder needs

*versus a 2018 baseline

Q4 AND FULL YEAR

GUIDANCE

Fourth Quarter 2025 Guidance

Sequential Business Outlook:

- **Consolidated**
  - Net Sales: Expected to decrease 10-15% sequentially
  - Adjusted EBITDA: Expected to range between $130 million and $160 million
  - Corporate Expenses as an offset to Adjusted EBITDA: Expected to range between $40 million and $45 million
  - Capital Expenditures: Approximately $50 million
  - Free Cash Flow Conversion: Expected to range 50-70%
- **TSS**
  - Net Sales: Expected to decline in the high-teens to low-twenties (%) sequentially, driven by overall traditional refrigerant seasonality
  - Adjusted EBITDA: Expected to approximate $125 million to $140 million, primarily driven by the referenced seasonality
- **TT**
  - Net Sales: Expected to decrease by high single-digits to low-teens (%) sequentially, driven by seasonality, regional sales mix, and near-term destocking
  - Adjusted EBITDA: Expected to approximate $15 million to $20 million, due to adjustments to production volumes for near-term demand signals
- **APM**
  - Net Sales: Expected to decrease by low single-digits (%) sequentially due to market weakness in the industrial end markets
  - Adjusted EBITDA: Expected to approximate $30 million to $40 million, driven by a return to normal operations at the Washington Works U.S. site

Full Year 2025 Outlook

Net Sales	$5.7B - $5.8B
Adjusted EBITDA	$745M - $770M
CapEx	~$220M

APPENDIX

TSS Segment Net Sales and Adjusted EBITDA (Unaudited)[5]





Net Sales: The 8% year-over-year volume increase was driven by stronger demand for Opteon™ Refrigerant blends in connection with the stationary air conditioning (AC) transition under the U.S. AIM Act, partially offset by lower volumes for Freon™ Refrigerant products under this regulatory transition. The 11% year-over-year increase in pricing was primarily attributed to stronger Opteon™ Refrigerant aftermarket demand.

Adjusted EBITDA: The increase was primarily driven by volume and price increases due to increased demand for Opteon™ Refrigerant blends products in connection with the stationary AC regulatory transition as referenced above, partially offset by input cost increases driven by R32 paired with one-time costs associated with our liquid cooling product development.

TT Segment Net Sales and Adjusted EBITDA (Unaudited)[5]

($ in millions)



($ in millions)



Net Sales: The year-over-year decrease was primarily driven by an 8% decrease in price globally, partially offset by favorable currency movements adding a slight 1% tailwind. Volumes showed a 2% decrease globally as the global TiO2 market remains challenged.

Adjusted EBITDA: The decline was driven primarily driven by the previously mentioned decrease in price paired with operational disruption costs of approximately $11 million.

APM Segment Net Sales and Adjusted EBITDA (Unaudited)[5]





Net Sales: Total decrease of 12% year-over-year was driven by a 15% decrease in volume which was partially offset by slight price and currency tailwinds. The decrease in volume was primarily driven by operational impacts related to the now resolved outage at the Washington Works site.

Adjusted EBITDA: The decrease was primarily due to the previously mentioned volume impact and outage-related approximating $20 million, partially offset by favorable pricing and currency.

Segment Net Sales (Unaudited)[5]

	2023				2024				2025		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Net sales by product group and segment											
Opteon™ refrigerants	195	200	170	145	200	227	205	178	279	375	368
Freon™ refrigerants	185	226	170	141	173	173	146	124	97	123	98
Foam, propellants, and other	114	107	104	94	81	119	117	88	90	99	94
Total Thermal & Specialized Solutions	494	533	444	380	454	519	468	390	466	597	560
Titanium dioxide and other minerals	$ 632	$ 707	$ 690	$ 651	$ 591	$ 677	$ 672	$ 632	$ 597	$ 657	$ 612
Total Titanium Technologies	632	707	690	651	591	677	672	632	597	657	612
Advanced materials	249	254	220	192	190	212	214	191	178	214	190
Performance solutions	144	140	129	134	113	133	140	133	116	132	121
Total Advanced Performance Materials	393	394	349	326	303	345	354	324	294	346	311
Performance chemicals and intermediates	30	26	18	11	14	13	14	13	11	15	12
Total Other Segment	30	26	18	11	14	13	14	13	11	15	12
Total net sales	$ 1,549	$ 1,660	$ 1,501	$ 1,368	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495

Segment Net Sales by Region (Unaudited)[5]

	2023				2024				2025		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Net sales by geographic region											
North America:											
Thermal & Specialized Solutions	$ 292	$ 319	$ 258	$ 207	$ 271	$ 308	$ 256	$ 194	$ 233	$ 336	$ 316
Titanium Technologies	262	277	273	242	246	274	270	236	267	282	252
Advanced Performance Materials	156	150	131	119	124	133	130	112	111	125	110
Other Segment	22	17	11	9	9	10	9	7	8	10	7
Total North America	732	763	673	577	650	725	665	549	619	753	685
Asia Pacific:											
Thermal & Specialized Solutions	53	56	42	41	39	53	55	53	53	59	69
Titanium Technologies	147	180	186	191	147	178	171	161	105	125	122
Advanced Performance Materials	147	145	133	129	105	127	138	148	115	147	138
Other Segment	2	4	3	3	3	2	3	3	2	3	3
Total Asia Pacific	349	385	364	364	294	360	367	365	275	334	332
Europe, the Middle East, and Africa:											
Thermal & Specialized Solutions	100	106	85	78	92	103	98	69	98	112	87
Titanium Technologies	133	147	123	116	124	130	126	131	142	156	141
Advanced Performance Materials	76	85	70	66	63	72	70	53	56	60	52
Other Segment	5	4	3	—	2	1	2	2	1	2	2
Total Europe, the Middle East, and Africa	314	342	281	260	281	306	296	255	297	330	282
Latin America (1):											
Thermal & Specialized Solutions	49	52	59	54	52	55	59	74	82	90	88
Titanium Technologies	90	103	108	102	74	95	105	104	83	94	97
Advanced Performance Materials	14	14	15	11	11	13	16	11	12	14	11
Other Segment	1	1	1	—	—	—	—	1	—	—	—
Total Latin America	154	170	183	167	137	163	180	190	177	198	196
Total net sales	$ 1,549	$ 1,660	$ 1,501	$ 1,368	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495

1 LATAM includes Mexico.

Actual and Projected Disruption & Investment Costs (Unaudited)

($, millions)	2024					2025				
	Q1 - Act	Q2 - Act	Q3 - Act	Q4 - Act	Total	Q1 - Act	Q2 - Act	Q3 - Act	Q4 - Guide	Total
Disruption Costs										
Thermal & Specialized Solutions (TSS)										
Winter Storm	$ -	$ -	$ -	$ -	$ -	$ 5	$ -	$ -	$ -	$ 5
Titanium Technologies (TT)										
Impacts from Altamira Outage	-	8	18	-	26	-	-	-	-	-
Winter Storm Impact	-	-	-	-	-	7	-	-	-	7
Rail Impact to Ore Mix	-	-	-	-	-	-	15	-	-	15
Operational Disruption	-	-	-	-	-	-	8	11	-	19
Total TT	-	8	18	-	26	7	23	11	-	41
Advanced Performance Materials (APM)										
Higher Deferred Maintenance Costs	-	-	-	-	-	5	-	-	-	5
Outage/Idling Costs & Related Impacts	-	-	-	-	-	-	-	20	4	24
Total APM	-	-	-	-	-	5	-	20	4	29
Corporate Expenses										
Internal Review Costs	12	11	2	2	27	3	1	2	-	6
olied in consolidation only)										-
TT Transformation Plan	-	11	3	2	16	1	-	-	-	1
Other Transformation Costs	-	-	-	-	-	-	2	3		5
Total Unallocated	-	11	3	2	16	1	2	3	-	6
Total Costs	**$ 12**	**$ 30**	**$ 23**	**$ 4**	**$ 69**	**$ 21**	**$ 26**	**$ 36**	**$ 4**	**$ 87**
Investment Costs										
TSS - Liquid Cooling & Next Generation Refrigerants	$ 5	$ 4	$ 5	$ 4	**$ 18**	$ 5	$ 5	$ 22	$ 8	**$ 40**

Segment Net Sales and Adjusted EBITDA (Unaudited)[5]

	2023				2024				2025		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Segment Net Sales											
Thermal & Specialized Solutions	$ 494	$ 533	$ 444	$ 380	$ 454	$ 519	$ 468	$ 390	$ 466	$ 597	$ 560
Titanium Technologies	632	707	690	651	591	677	672	632	597	657	612
Advanced Performance Materials	393	394	349	326	303	345	354	324	294	346	311
Other Non-Reportable Segment	30	26	18	11	14	13	14	13	11	15	12
Total Company Net Sales	$ 1,549	$ 1,660	$ 1,501	$ 1,368	$ 1,362	$ 1,554	$ 1,508	$ 1,359	$ 1,368	$ 1,615	$ 1,495
Segment Adjusted EBITDA											
Thermal & Specialized Solutions	$ 185	$ 214	$ 162	$ 124	$ 150	$ 160	$ 139	$ 122	$ 141	$ 207	$ 194
Titanium Technologies	70	87	69	64	69	83	78	70	50	47	25
Advanced Performance Materials	84	81	68	40	30	45	38	47	32	50	14
Other Non-Reportable Segment	10	5	2	-	2	3	3	-	1	4	2
Corporate Expenses	(45)	(63)	(54)	(50)	(55)	(77)	(54)	(69)	(57)	(53)	(38)
Segment Adjusted EBITDA Margin											
Thermal & Specialized Solutions	37%	40%	36%	33%	33%	31%	30%	31%	30%	35%	35%
Titanium Technologies	11%	12%	10%	10%	12%	12%	12%	11%	8%	7%	4%
Advanced Performance Materials	21%	21%	20%	12%	10%	13%	11%	15%	11%	14%	5%
Other Non-Reportable Segment	33%	19%	13%	0%	14%	23%	21%	0%	9%	27%	17%

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio[5] (Page 1/2)

($ in millions except per share amounts)	Three Months Ended September 30,				Three Months Ended June 30,		Twelve Months Ended September 30,	
	2025		2024		2025		2025	2024
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
Income (loss) before income taxes	$ 51		$ (32)		$ (261)		$ (209)	$ 31
Net income (loss) attributable to Chemours	$ 60	$ 0.40	$ (32)	$ (0.22)	$ (381)	$ (2.54)	$ (335)	$ 59
Non-operating pension and other post-retirement benefit income	(4)	(0.03)	(2)	(0.01)	(2)	(0.01)	(7)	(6)
Exchange losses, net	1	0.01	—	—	4	0.03	11	23
Restructuring, asset-related, and other charges	4	0.03	43	0.29	18	0.12	61	61
Goodwill impairment charge	—	—	56	0.37	—	—	—	56
Loss on extinguishment of debt	—	—	—	—	—	—	1	—
Gain on sales of assets and businesses, net	(7)	(0.05)	—	—	—	—	(8)	(7)
Transaction costs	—	—	—	—	2	0.01	4	9
Qualified spend recovery	(13)	(0.09)	(7)	(0.05)	(13)	(0.09)	(39)	(33)
Litigation-related charges	2	0.01	3	0.02	299	1.99	301	87
Environmental charges	13	0.09	—	—	60	0.40	88	—
Adjustments made to income taxes	(23)	(0.15)	5	0.03	171	1.14	150	(11)
(Benefit from) provision for income taxes relating to reconciling items	(3)	(0.02)	(5)	(0.03)	(71)	(0.47)	(81)	(29)
Adjusted Net Income	$ 30	$ 0.20	$ 61	$ 0.40	$ 87	$ 0.58	$ 146	$ 209
Net income attributable to non-controlling interests	—		—		1		1	—
Interest expense, net	68		68		67		268	260
Depreciation and amortization	80		73		79		311	295
All remaining provision for income taxes	17		—		19		56	12
Adjusted EBITDA	$ 195		$ 202		$ 253		$ 782	$ 776

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio[5] (Page 2/2)

($ in millions except per share amounts)	Three Months Ended September 30, 2025		Three Months Ended September 30, 2024		Three Months Ended June 30, 2025		Twelve Months Ended September 30, 2025	Twelve Months Ended September 30, 2024
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
Adjusted EBITDA	$ 195		$ 202		$ 253		$ 782	$ 776
Total debt principal							$ 4,185	$ 4,078
Less: Cash and cash equivalents							(613)	(596)
Total debt principal, net							$ 3,572	$ 3,482
Net Leverage Ratio (calculated using GAAP earnings)							(17.1)x	112.3x
Net Leverage Ratio (calculated using Non-GAAP earnings)							4.6x	4.5x
Weighted-average number of common shares outstanding - basic	150,320,265		149,697,616		150,238,691			
Weighted-average number of common shares outstanding - diluted	150,781,614		150,180,195		150,506,761			
Basic earnings (loss) per share of common stock (2)	$ 0.40		$ (0.22)		$ (2.54)			
Diluted earnings (loss) per share of common stock (1) (2)	$ 0.40		$ (0.22)		$ (2.54)			
Adjusted basic earnings per share of common stock (2)	$ 0.20		$ 0.41		$ 0.58			
Adjusted diluted earnings per share of common stock (1) (2)	$ 0.20		$ 0.40		$ 0.58			

(1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended June 30, 2025 and September 30, 2024. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended June 30, 2025 and September 30, 2024 as Adjusted Net Income was in a net income position.

(2) Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.

* Note: $ per share columns may not sum due to rounding.

GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation

($ in millions)	Three Months Ended			Nine Months Ended	
	September 30,		June 30,	September 30,	
	2025	2024	2025	2025	2024
Cash flows provided by (used for) operating activities	$ 146	$ 139	$ 93	$ 127	$ (771)
Less: Purchases of property, plant, and equipment	(41)	(76)	(43)	(168)	(251)
Free Cash Flows	$ 105	$ 63	$ 50	$ (41)	$ (1,022)
Adjusted EBITDA	195	202	253	614	600
Free Cash Flow Conversion	54%	31%	20%	(7)%	(170)%

1. For the nine months ended September 30, 2024, operating cash outflows includes the release of the $606 million of cash and cash equivalents deposited in the qualified settlement fund per the terms of the U.S. public water system settlement agreement.

2025 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income, Estimated Adjusted EBITDA(*)

(In millions except per share amounts)	(Estimated) Year Ending December 31, 2025 Low	High
Net loss attributable to Chemours	$ (335)	$ (318)
Restructuring, transaction, and other costs, net (1)	462	462
Adjusted Net Income	127	144
Interest expense, net	273	273
Depreciation and amortization	317	317
All remaining provision for income taxes	28	36
Adjusted EBITDA	$ 745	$ 770

(1) Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.

(*) The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates.

Chemours™

® 2025 CHEMOURS. ALL RIGHTS RESERVED